Access cutting-edge amyotrophic lateral sclerosis treatment through this clinical trial at a research site in Santa Barbara. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Santa Barbara location
Preparing your pre-screening questions…
Access amyotrophic lateral sclerosis specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related amyotrophic lateral sclerosis treatment provided free
Check if you qualify for this amyotrophic lateral sclerosis clinical trial in Santa Barbara, CA
No-Cost Study Care
Local to Santa Barbara
Convenient for CA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This study compares a wearable brain-computer interface (BCI) communication device with the eye-tracking communication devices that people with ALS already use. As ALS progresses, speech is lost and many people come to rely on an eye-tracking speech generating device. Eye-tracking performance can decline as oculomotor control is affected, and some people reach a point where it no longer works reliably for them. The Cognixion ONE device adds a brain-computer interface input, which does not depend on eye movement, alongside an AI-assisted communication application. Thirty adults with ALS who currently use a Tobii Dynavox or Smartbox eye-tracking device will take part. Each participant uses three communication options at home over a 12-week period: their own eye-tracking device, the Cognixion ONE device with a head-worn augmented-reality display, and the Cognixion ONE device with a screen-based display. For some sessions the option is assigned; for others the participant chooses. The main measure is how much time participants voluntarily choose to spend using each option. That choice is treated as the clearest signal of which option genuinely works better for them. The study also measures communication speed and accuracy, usability, workload, quality of life, and caregiver burden. The Cognixion ONE device is an investigational research device. It is not approved or cleared by the U.S. Food and Drug Administration for any medical use.
Sponsor: Cognixion
Yes, this clinical trial (NCT07871071) has an active research site in Santa Barbara, CA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for amyotrophic lateral sclerosis treatment options in Santa Barbara, CA, this clinical trial (NCT07871071) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Santa Barbara research site is actively enrolling participants for this clinical trial. You'll receive care from experienced amyotrophic lateral sclerosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all amyotrophic lateral sclerosis clinical trials near you to find additional studies recruiting in your area.
See all als clinical trials recruiting in Santa Barbara — not just this study.
Browse ALS Trials in Santa Barbara →